Mannstadt Laboratory

About the Lab

My research focuses on parathyroid function and disease. As a physician-scientist, I have the great fortune that my research spans the basic, translational, and clinical realms of the disease.

Our basic research focuses on the parathyroid-specific master regulator GCM2 and its mode of action as well as the alpha subunit of the G protein G11. Our translational projects include research on a long-acting PTH and its use in hypoparathyroidism. Our clinical studies focus on the long-term consequences of hypoparathyroidism and its current treatment, and on using PTH (1-84) for this disease

Research Projects

Mode of Action of GCM2, the essential parathyroid transcription factor

GCM2 is a transcription factor that is essential for the development of parathyroid glands. Our previous work showed that heterozygous mutations in GCM2 cause a familial form of hypoparathyroidism. We are currently investigating target genes and binding partners for this transcription factor, as well as the role of the continued expression of this transcription factor in adult parathyroid tissue.

Mutations in the alpha subunit of G11 and hypoparathyroidism

We found that heterozygous mutations in the alpha subunit of G11 can cause primary hypoparathyroidism; recent functional studies have shown that this mutant G protein fails to normally transmit the signal of the calcium-sensing receptor. Our research is aiming to unravel the function of G11 in the parathyroid glands.

Long-acting PTH for hypoparathyroidism

Clinical Trials

Dr. Mannstadt is the site-PI for the following clinical trials:

A prospective, observational, natural history registry, designed to collect data on patients with chronic hypoparathyroidism. No study-defined procedures will be required, and if available, a select set of data will be collected at baseline and at least annually. Learn more

A study designed to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with ADH1. Learn more

A study investigating the safety and efficacy of eneboparatide (AZP-3601) in patients with chronic hypoparathyroidism (cHP). Learn more

Publications

View recent publications from the laboratory. Some full text articles may require a subscription.

View all Publications in PubMed